Chilvery S, Yelne A, Khurana A, Saifi MA, Bansod S, Anchi P, et al
requires medical knowledge to minimize risk Intranasal Intranasal delivery to target the olfactory bulb and trans-cribriform access to the brain has been explored for some peptides: Theoretical advantage: Direct CNS access, bypassing the blood-brain barrier Reality: Intranasal peptide formulations are complex and Dihexa is not commonly available in this form Evidence: No published data on intranasal Dihexa efficacy or safety Oral Bioavailability: Approximately 38% The most commonly cited bioavailability figure for oral Dihexa is approximately 38%
Roy, S., Amin, S., & Roy, S
Walther-Antnio, M
It is most relevant during GLP-1 use or caloric deficit, when fatigue is part of the picture, with age-related NAD+ decline, or when progress stalls after a clean first month
For more on oral versus injectable administration, see our next article, the BPC-157 Administration Guide
